Bellerophon Therapeutics LLC (Nasdaq: BLPH) presented positive data from a clinical trial of INOpulse(R) to treat pulmonary arterial hypertension sending the stock price soaring $1.17 to $5.29.
Positive study data for Bellerophon Therapeutics
September 30, 2015 at 15:03 PM EDT
